Key facts
- Cytrellis’s last known valuation is $38.1M (Dec 2024).
- It has raised $116.8M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($50.0M) in Jan 2021.
- Notable investors include D1 Capital Partners, ARCH Venture Partners, Venrock, Sands Capital, Biomatics Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Cytrellis
Funding rounds
2 roundsAbout Cytrellis
Developer of an aesthetic technology designed to eliminate skin-related problems without any surgery. The company's technology includes hand-held devices and consumables that are designed to remove sagging skin without any scarring to improve age-related skin changes and to help restore youthful beauty, enabling medical practitioners to provide an improved quality of life for patients.
- Industry
- Other Devices and Supplies
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2011
- Employees
- 51
- Website
- cytrellis.com/
- Ownership
- Privately Held (backing)
Cytrellis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cytrellis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cytrellis in its N-PORT filings yet. We sweep new filings monthly.